NCT01573663

Brief Summary

The purpose of this study is to evaluate the drug-durg interaction between ambroxol and levodropropizine.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
21

participants targeted

Target at P25-P50 for phase_1 healthy

Timeline
Completed

Started Feb 2012

Shorter than P25 for phase_1 healthy

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2012

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2012

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2012

Completed
4 days until next milestone

First Submitted

Initial submission to the registry

April 5, 2012

Completed
4 days until next milestone

First Posted

Study publicly available on registry

April 9, 2012

Completed
Last Updated

July 19, 2012

Status Verified

April 1, 2012

Enrollment Period

2 months

First QC Date

April 5, 2012

Last Update Submit

July 18, 2012

Conditions

Keywords

AmbroxolLevodropropizineDrug-drug interaction

Outcome Measures

Primary Outcomes (2)

  • AUClast

    0-48hrs

  • Cmax

    0-48hrs

Secondary Outcomes (3)

  • Tmax

    0-48hrs

  • T1/2

    0-48hrs

  • AUCinf

    0-48hrs

Study Arms (3)

Ambroxol and Levodropropizine

EXPERIMENTAL
Drug: Ambroxol and Levodropropizine

Ambroxol

ACTIVE COMPARATOR
Drug: Ambroxol

Levodropropizine

ACTIVE COMPARATOR
Drug: Levodropropizine

Interventions

Ambroxol HCl 30mg \& Levodropropizine 60mg, PO, Single dose

Ambroxol and Levodropropizine

Ambroxol HCl 30mg, PO, single dose

Ambroxol

Levodropropizine 60mg, PO, single dose

Levodropropizine

Eligibility Criteria

Age20 Years - 55 Years
Sexmale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Healthy male
  • Age between 20 and 55
  • Signed informed consent

You may not qualify if:

  • Has a history of hypersensitivity to IP ingredients
  • Hypotension or hypertension
  • Has a history of acute infection within 14 days of screening

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Samsung medical center

Seoul, South Korea

Location

MeSH Terms

Interventions

Ambroxoldipropizine

Intervention Hierarchy (Ancestors)

BromhexineAniline CompoundsAminesOrganic ChemicalsCyclohexylamines

Study Officials

  • Wooseong Huh, MD

    Samsung Medical Center

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 5, 2012

First Posted

April 9, 2012

Study Start

February 1, 2012

Primary Completion

April 1, 2012

Study Completion

April 1, 2012

Last Updated

July 19, 2012

Record last verified: 2012-04

Locations